Organization (Hospital)
Azienda Ospedaliera Universitaria Policlinico "G. Martino"
ClinicalTrials.gov lists Azienda Ospedaliera Universitaria Policlinico "G. Martino" as lead sponsor of 16 trials. It has 6 active development programs and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 4 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Azienda Ospedaliera Universitaria Policlinico "G. Martino": 16 lead-sponsored trials and 1 legal-entity registration.
Disease areas (61)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Heart Failure | 3 |
| Pain | 3 |
| Chronic Pain | 2 |
| Cognitive Dysfunction | 2 |
| Dwarfism | 2 |
Showing 5 of 61 disease areas.
Trials by start year as sponsor or collaborator (14)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 8 |
| 2024 | 2 |
| 2023 | 8 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 3 |
| 2017 | 1 |
| 2016 | 2 |
Showing 10 of 14 years.
Recruitment duration, a model prediction: none of the 16 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (6)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| P2Y12 inhibitor de-escalation | Coronary Artery Disease | Phase 3 | 1 |
| P2Y12 inhibitor de-escalation | Coronary Disease | Phase 3 | 1 |
| P2Y12 inhibitor de-escalation | Acute Coronary Syndrome | Phase 3 | 1 |
| Active Comparator | Colic | Not reported | 1 |
| Verum | Colic | Not reported | 1 |
Showing 5 of 6 active programs.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| melatonin in children premedication | 1 |
| midazolam in children premedication | 1 |
| Nabilone | 1 |
| HYALURONIC ACID | 1 |
Journals published in (222)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| AJR. American journal of roentgenology | 5 |
| Pain | 5 |
| Pediatrics | 4 |
| The New England journal of medicine | 4 |
| British journal of pharmacology | 3 |
Showing 5 of 222 journals.
Organization relationships (41)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Co sponsors trial with | 4 |
| Istituti di Ricovero e Cura a Carattere Scientifico | Co sponsors trial with | 4 |
| IRCCS National Neurological Institute "C. Mondino" Foundation | Co sponsors trial with | 3 |
| Federico II University | Co sponsors trial with | 2 |
| Azienda Ospedaliero Universitaria Policlinico Modena | Co sponsors trial with | 2 |
Showing 5 of 41 relationships.
Latest dated events (38)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 38 events.
Biomarker capability evidence (16)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ARC | Trial sponsor | Named in trial inclusion criteria |
| CBS | Trial collaborator | Named in trial inclusion criteria |
| DMD | Trial collaborator | Named in trial inclusion criteria |
| FOLH1 | Trial collaborator | Named in trial inclusion criteria |
| MECP2 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 16 evidence rows.
Biomarkers this organization publishes on (3)
Shown in this order: most publications first.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.